Keith W. Marshall - 14 Nov 2021 Form 4 Insider Report for Prometheus Biosciences, Inc.

Role
Chief Financial Officer
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Keith W. Marshall
Issuer symbol
N/A
Transactions as of
14 Nov 2021
Net transactions value
$0
Form type
4
Filing time
16 Nov 2021, 20:08:40 UTC
Next filing
20 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Award $0 +102,155 $0.000000 102,155 14 Nov 2021 Common Stock 102,155 $36.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option will vest on November 14, 2022, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date.